会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • MODIFIED ERYTHROPOIETIN TO WHICH WATER-SOLUBLE LONG-CHAIN MOLECULE IS ADDED
    • 添加了可溶性长链分子的改良的红细胞膜蛋白
    • US20120264687A1
    • 2012-10-18
    • US13395534
    • 2010-09-15
    • Nobutaka TaniToshihide FujiiHiroyuki WatanabeHirofumi Maeda
    • Nobutaka TaniToshihide FujiiHiroyuki WatanabeHirofumi Maeda
    • A61K38/18A61P7/06
    • A61K9/0019A61K38/1816A61K47/60
    • An object of the invention is to provide a pharmaceutical composition that contains erythropoietin as the active ingredient and has, when administered in humans and/or animals, a hematopoietic effect that lasts for not less than seven days. The invention provides a pharmaceutical composition containing, in an amount equal to not less than 50% of the total erythropoietin, erythropoietin to which two or more water-soluble long-chain molecules are added. The invention also provides a pharmaceutical composition containing erythropoietin to which a water-soluble long-chain molecule is added, wherein the water-soluble long-chain molecule has a molecular weight of not less than 30 kDa. The invention further provides a pharmaceutical composition containing erythropoietin to which a water-soluble long-chain molecule is added, wherein the water-soluble long-chain molecule has a branched chain.
    • 本发明的目的是提供一种含有促红细胞生成素作为活性成分并且在人和/或动物中施用时持续不少于7天的造血作用的药物组合物。 本发明提供一种药物组合物,其含量等于不少于总促红细胞生成素的50%,红细胞生成素,其中加入了两种或更多种水溶性长链分子。 本发明还提供含有促红细胞生成素的药物组合物,其中加入水溶性长链分子,其中水溶性长链分子的分子量不小于30kDa。 本发明还提供含有促红细胞生成素的药物组合物,其中加入水溶性长链分子,其中所述水溶性长链分子具有支链。
    • 7. 发明授权
    • Method for immobilizing ligand or compound having ligand bonded thereto
    • 固定具有配体键合的配体或化合物的方法
    • US5866387A
    • 1999-02-02
    • US894782
    • 1997-08-28
    • Eiji OginoKazuo SuzukiNobutaka Tani
    • Eiji OginoKazuo SuzukiNobutaka Tani
    • B01J20/32C12N11/04C12N11/06C12N11/08G01N33/544
    • B01J20/3274B01J20/3204B01J20/321B01J20/3212B01J20/3251B01J20/3255Y10S530/814Y10S530/815Y10S530/816
    • There is provided a method for immobilizing a ligand by reacting a solvent-insoluble carrier having aldehyde group with a compound shown by the general formula: ##STR1## wherein X is --S-- or --O--, R.sup.1, R.sup.2 and R.sup.6 are the same or different, each of which is hydrogen atom or an alkyl group having 1 to 4 carbon atoms, R.sup.3 is hydrogen atom or a substituent wherein an atom adjacent to nitrogen atom shown in the above-mentioned general formula has no unsaturated bond, R.sup.4, R.sup.5 and R.sup.7 are arbitrary substituents; provided that only one partial chemical structure of HX--C--C--NHR.sup.3 wherein X and R.sup.3 are the same as defined above or HX--C--C--C--NHR.sup.3 wherein X and R.sup.3 are the same as defined above is contained in one compound described above by which, a ligand or a compound to which a ligand is bonded can react specifically and effectively with aldehyde group in a solvent-insoluble carrier at a prescribed position to form a stable bond.
    • PCT No.PCT / JP96 / 00450 Sec。 371日期1997年8月28日 102(e)日期1997年8月28日PCT 1996年2月26日PCT公布。 第WO96 / 26786号公报 日期1996年6月9日提供了通过使具有醛基的溶剂不溶性载体与通式如下的化合物反应来固定配体的方法:其中X是-S-或-O-,R 1,R 2 R6相同或不同,分别为氢原子或碳原子数1〜4的烷基,R3为氢原子或上述通式所示的与氮原子相邻的原子没有不饱和基团的取代基 键,R4,R5和R7是任意的取代基; 只要其中X和R 3与上述定义相同的HX-CC-NHR3的仅一部分化学结构或其中X和R 3与上述相同的HX-CCC-NHR 3包含在上述一种化合物中,其中a 配体或配体所结合的化合物可以在规定的位置上与溶剂不溶性载体中的醛基特异性和有效地反应以形成稳定的键。
    • 9. 发明授权
    • Method and apparatus for treating blood constituents
    • 治疗血液成分的方法和装置
    • US4696670A
    • 1987-09-29
    • US795663
    • 1985-11-06
    • Michikazu OhnishiNobutaka Tani
    • Michikazu OhnishiNobutaka Tani
    • A61M1/14A61M1/34A61M1/36A61M31/00
    • A61M1/3472A61M1/3427A61M1/3606A61M1/3646A61M2202/0415A61M2202/046Y10S128/03
    • A method for treating circulatory fluid constituents with an apparatus which includes a first switching device which connects the upstream side of a first circulatory fluid treatment device with a flow of circulatory fluid from a source, and a second switching device which connects the downstream side of the first circulatory fluid treatment device with a destination of the circulatory fluid. Next, the second switching device maintains the flow of circulatory fluid to the destination from the downstream side of the first circulatory fluid treatment device, the upstream side of the first circulatory fluid treatment device is disconnected with the flow of circulatory fluid from the source, and further a third switching device connects the upstream side of a second circulatory fluid treatment device to the flow of a circulatory fluid from the source, and a fourth switching device connects the downstream side of the second circulatory fluid treatment device to communicate with the upstream side of the first circulatory fluid treatment device. Finally, the third switching device maintains the flow of circulatory fluid from the source into the upstream side of the second circulatory fluid treatment device, the downstream side of the first circulatory fluid treatment device is disconnected from sending the flow of circulatory fluid to the destination, and a fifth switching device connects the downstream side of the second circulatory fluid treatment device with the destination for the flow of circulatory fluid thereto.
    • 一种用于利用包括将第一循环流体处理装置的上游侧与来自源的循环流体流连接的第一开关装置的设备和用于连接第一循环流体处理装置的下游侧的第二开关装置的装置的方法, 具有循环流体目的地的第一循环流体处理装置。 接下来,第二切换装置将第一循环流体处理装置的下游侧的循环流体的流动维持到目的地,第一循环流体处理装置的上游侧与源的循环流体的流动断开, 另外,第三开关装置将第二循环流体处理装置的上游侧连接到来自源的循环流体的流动,第四开关装置将第二循环流体处理装置的下游侧连接到第二循环流体处理装置的上游侧 第一循环流体处理装置。 最后,第三开关装置维持循环流体从源流入第二循环流体处理装置的上游侧,第一循环流体处理装置的下游侧与循环流体流向目的地分离, 并且第五切换装置将第二循环流体处理装置的下游侧与循环流体流动的目的地连接。